RAC1 was significantly higher and associated with poor prognosis in HER2 (ERBB2) over-expressing tumours, although the range of RAC1 expression was similar between HER2+ and HER2− tumours (Figure S1). This evidence concerns the gene ERBB2 and neoplasm.